FDA’s FY 2025 User Fee Schedules Notch Increases of Up to 44 Percent

The FDA has posted six user fee schedules for FY 2025 on the Federal Register showing increases of up to 44 percent — the highest being for biosimilars.
Source: Drug Industry Daily